Replies to post #483753 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Writing on the wall.

Further reviewing ERC’s decision to withdraw Gliovac application from the marketing authorization process, I am struck by the 180 degree difference with DCVax-l. In short, robustness in safety, benefit to risk ratio, trial size and quality, manufacturing validity and consistency and efficacy thus far presented strongly suggest DCVax-l would have immediately displaced Gliovac in the application process. The question remains when (and where) will NWBO apply?